Close
Achema middle east
swop processing & packaging

Dr. Reddy’s announces three generic product launches in the US Market

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Pharmaceutical Manufacturing Fire Safety Through Skilled Workforce Training

Pharmaceutical manufacturing environments handle a variety of sensitive and...

LTS Grows U.S. Footprint by Buying CDMO Renaissance Lakewood

As the U.S. production investments continue to roll in...

US Tariffs on Pharma Exports from Singapore Deferred

As originally reported by the Straits Times and also shared...

UK Exchequer Wants More Pharma Investment Coming in Britain

Rachel Reeves, the UK Chancellor of the Exchequer, has...

Dr. Reddy’s Laboratories announced that it has launched the following three products in the US market: Donepezil Hydrochloride tablets (5mg and 10mg strengths), a bioequivalent generic version of ARICEPT® tablets*. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Donepezil HCl tablets on May 31, 2011. Both strengths of Dr. Reddy’s Donepezil Hydrochloride tablets are available in 30, 90 and 500 count bottles.

Venlafaxine Hydrochloride Extended Release capsules (37.5mg, 75mg and 150mg strengths), a bioequivalent generic version of EFFEXOR XR® Extended Release capsules**. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Venlafaxine Hydrochloride Extended Release Capsules on May 05, 2011. All three strengths of Dr. Reddy’s Venlafaxine Hydrochloride Extended Release Capsules are available in 30, 90 and 500 count bottles.

Letrozole tablets, USP (2.5mg), a bioequivalent generic version of FEMARA®***. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Letrozole tablets, USP on June 3, 2011. Dr. Reddy’s Letrozole tablets, USP are available in 30 count bottles.

Latest stories

Related stories

Pharmaceutical Manufacturing Fire Safety Through Skilled Workforce Training

Pharmaceutical manufacturing environments handle a variety of sensitive and...

LTS Grows U.S. Footprint by Buying CDMO Renaissance Lakewood

As the U.S. production investments continue to roll in...

US Tariffs on Pharma Exports from Singapore Deferred

As originally reported by the Straits Times and also shared...

UK Exchequer Wants More Pharma Investment Coming in Britain

Rachel Reeves, the UK Chancellor of the Exchequer, has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »